Drug intelligence / Profile preview

VM-NEU-002

Development stage: Preclinical
Lead developer: VivaMed
Modality: Small Molecules

Overview

VM-NEU-002 is an investigational small molecule drug candidate being developed by VivaMed BioPharma for the treatment of Alzheimer's Disease. Currently in the IND-enabling phase of development, it is part of the company's neurology-focused pipeline (VM-NEU series). VivaMed BioPharma specializes in developing and repurposing therapies for central nervous system (CNS) disorders, pain, and psychiatry. While the specific molecular target and mechanism of action for VM-NEU-002 have not been publicly disclosed, the program aims to address neurodegenerative pathology associated with Alzheimer's Disease.

Beyond the preview

Go deeper on VM-NEU-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-NEU-002.

Explore the full profile